Health Care : Current Reviews

New advances in breast cancer treatment

3^rd Indo-Global Summit & Expo on Healthcare

October 05-07, 2015 New Delhi, India

Roberto Hegg

University of Sao Paulo, Brazil

Posters-Accepted Abstracts: Health Care: Current Reviews

Abstract:

While some promising new treatments for breast cancer are years away from regular treatment regimens, others are on the market or just around the corner. New breast cancer treatments are available now. Over the past year, doctors have learned a lot more about many targeted therapies that very soon may be helping millions of women live longer and healthier lives after learning they have breast cancer. Most of the recent advances in the last few years occurred in her 2 positive disease with Trastuzumab-Pertuzumab-Docetaxel association. Study TOC4129g (WO20698), initiated in 2008 is a randomized Phase III study (CLEOPATRA) for the first-line treatment of HER2-positive MBC. The median PFS was 12.4 months in the control arm, compared with 18.5 months in patients treated with trastuzumab and docetaxel with pertuzumab (experimental arm) (HR=0.62; 95% CI: 0.51-0.75; p=0.001). The confirmatory analysis for overall survival (OS) performed after 267 deaths and 69% of the pre-specified total number of events demonstrate a 3-year OS rate of 72% in patients treated with trastuzumab and docetaxel with pertuzumab compared with 62% in patients treated in the comparator arm (HR 0.66 (95% CI: 0.52-0.84; p=0.0008). The safety profile was generally similar in the two arms with no increase in left ventricular systolic dysfunction. The rates of febrile neutropenia and diarrhea of Grade 3 or above were higher in the experimental arm. Moreover, some improvement was seen in hormone positive disease with her 2 negative.

Biography :

Email: robertohegg@gmail.com